BST02 is being developed to treat liver cancer, including hepatocellular carcinoma and cholangiocarcinoma. Credit: Peakstock / Shutterstock.com.

The US Food and Drug Administration (FDA) has granted fast track designation (FTD) to Biosyngen’s T cell therapy BST02 for treating liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.

The designation will accelerate the clinical trial process and marketing registration for BST02.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

BST02 utilises adoptive immune cell therapy technology, expanding the patient’s own tumour-infiltrating lymphocytes. This approach offers potential benefits over standard tumour-infiltrating lymphocyte (TIL) therapies, including the ability to be cryopreserved and transported and a reduced requirement for high doses of interleukin-2.

In October 2023, the company received FDA approval to commence the Phase I/II clinical trials of the cell therapy.

The China National Drug Administration’s Center for Drug Evaluation granted approval for the trial in December.

This marks a significant milestone as BST02 becomes the first TIL cell therapy drug for liver cancer to enter clinical stages globally.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FTD for BST02 follows a similar designation for another Biosyngen product, BRG01, in July 2023.

Biosyngen aims to continue its research efforts to improve patient outcomes worldwide.

Biosyngen co-founder and CEO Michelle Chen expressed her gratitude to the FDA for recognising the company’s fourth product.

She highlighted the company’s commitment to advancing cancer cell therapy across the globe and offering new treatments for a diverse patient population.

Chen reaffirmed the company’s dedication to using its advanced technology platforms to deliver accessible therapies for patients around the world.

In September 2023, the company received FDA IND clearance for a Phase I/II trial of its therapy, BRL03, to treat lung cancer, gastric cancer and other advanced solid tumours.

BRL03 is the first T cell receptor product developed by the company to enter the clinics.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.